{
    "brief_title": "Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Pyrotinib+Trastuzumab+Capecitabine', 'Trastuzumab+Pertuzumab/Trastuzumab']",
    "drugs_list": [
        "Pyrotinib+Trastuzumab+Capecitabine",
        "Trastuzumab+Pertuzumab/Trastuzumab"
    ],
    "diseases": "['Breast Cancer', 'Adjuvant Therapy']",
    "diseases_list": [
        "Breast Cancer",
        "Adjuvant Therapy"
    ],
    "enrollment": "206.0",
    "inclusion_criteria": "inclusion criteria: \n\n Female patients aged \u2265 18 years and \u2264 75 years old with primary breast cancer \n\n ECOG score 0  \n\n  1 \n\n Breast cancer meets the following criteria: 1\uff09Histologically or pathologically confirmed invasive breast cancer, primary tumor stage determined by standard evaluation methods\uff1acT1-4/N0-3/M0. 2\uff09Pathologically confirmed HER2-expressing positive breast cancer, defined as > 10% immunoreactive cells with immunohistochemical (IHC) score of 3 + or in situ hybridization (ISH) results of HER2 gene amplification. 3)Known hormone receptor status (ER and PgR). 4)Neoadjuvant therapy (including: at least 9 weeks of trastuzumab treatment and at least 9 weeks of taxane chemotherapy) \n\n Primary breast cancer lesion or lymph node invasive cancer confirmed by pathology after neoadjuvant therapy (residual invasive breast cancer lesion > 2 cm or axillary lymph node positive with macrometastasis assessed by central laboratory) \n\n No more than 12 weeks between end of surgery (without post-operative radiotherapy) and randomisation or 6 weeks between end of post-operative radiotherapy and randomisation \n\n Required laboratory values including following parameters: \n\n ANC: \u2265 1.5 x 109/L Platelet count: \u2265 90 x 109/L Hemoglobin: \u2265 9.0 g/dL Total bilirubin: \u2264 1.5 x upper limit of normal, ULN ALT and AST: \u2264 1.5 x ULN BUN and creatine clearance rate: \u2265 50 mL/min LVEF: \u2265 55% QTcF: < 470 ms \n\n ",
    "exclusion_criteria": ": \n\n 1) Stage IV (metastatic) breast cancer; \n\n 2) inflammatory breast cancer; \n\n 3) Previous anti-tumor therapy or radiotherapy for any malignancy, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma; \n\n 4) Receiving anti-tumor therapy in other clinical trials, including bisphosphonate therapy or immunotherapy (except radiotherapy and endocrine therapy during treatment); \n\n 5) Receiving any anti-tumor therapy within 28 days before enrollment; \n\n 6) Peripheral neuropathy \u2265 Grade 2 as specified by NCI CTCAE; \n\n 7) Receiving pyrrolidone or other anti-HER2 tyrosine kinase inhibitors; \n\n 8) Receiving anthracycline therapy with cumulative doses as follows: adriamycin > 240 mg/m2, epirubicin > 480 mg/m2; \n\n 9) Receiving major surgery unrelated to breast cancer before randomization, or the patient has not fully recovered from surgery",
    "brief_summary": "To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor/axillary lymph nodes) who did not achieve pCR after neoadjuvant therapy",
    "NCT_ID": "NCT05292742"
}